Laboratory of Neurogenetics, Department of Molecular Neuroscience, UCL Institute of Neurology London, UK.
Laboratory of Neurogenetics, Institute of Translational Pharmacology, National Research Council of Italy Rome, Italy.
Front Cell Neurosci. 2015 Feb 16;9:36. doi: 10.3389/fncel.2015.00036. eCollection 2015.
Spinocerebellar Ataxia type 6 (SCA6) is an autosomal dominant neurodegenerative disease characterized by late onset, slowly progressive, mostly pure cerebellar ataxia. It is one of three allelic disorders associated to CACNA1A gene, coding for the Alpha1 A subunit of P/Q type calcium channel Cav2.1 expressed in the brain, particularly in the cerebellum. The other two disorders are Episodic Ataxia type 2 (EA2), and Familial Hemiplegic Migraine type 1 (FHM1). These disorders show distinct phenotypes that often overlap but have different pathogenic mechanisms. EA2 and FHM1 are due to mutations causing, respectively, a loss and a gain of channel function. SCA6, instead, is associated with short expansions of a polyglutamine stretch located in the cytoplasmic C-terminal tail of the protein. This domain has a relevant role in channel regulation, as well as in transcription regulation of other neuronal genes; thus the SCA6 CAG repeat expansion results in complex pathogenic molecular mechanisms reflecting the complex Cav2.1 C-terminus activity. We will provide a short review for an update on the SCA6 molecular mechanism.
脊髓小脑性共济失调 6 型(SCA6)是一种常染色体显性遗传性神经退行性疾病,其特征为发病较晚,进行性缓慢,主要为单纯小脑性共济失调。它是与 CACNA1A 基因相关的三种等位基因疾病之一,该基因编码 P/Q 型钙通道 Cav2.1 的α1A 亚基,在大脑中表达,特别是在小脑。另外两种疾病是发作性共济失调 2 型(EA2)和家族性偏瘫性偏头痛 1 型(FHM1)。这些疾病表现出不同的表型,尽管它们经常重叠,但具有不同的发病机制。EA2 和 FHM1 分别是由于导致通道功能丧失和获得的突变引起的。相反,SCA6 与位于蛋白质胞质 C 末端尾部的短聚谷氨酰胺延伸有关。该结构域在通道调节以及其他神经元基因的转录调节中具有重要作用;因此,SCA6 CAG 重复扩展导致复杂的致病分子机制,反映了复杂的 Cav2.1 C 末端活性。我们将提供简短的综述,以更新 SCA6 的分子机制。